TriLink BioTechnologies plans to construct new mRNA manufacturing capabilities to serve late-phase drug developers in the field of life sciences.
The new facility features ISO 7 cleanrooms and increased mRNA manufacturing capacity, capable of producing batches ranging from 1g to over 50g. The facility also offers comprehensive in-house analytical services.
The new facility, designed to meet the growing market demand, is expected to contribute to the development of crucial mRNA therapeutics. It has been specifically designed for the cGMP manufacture of various mRNA-based applications, including in vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines.
In addition to state-of-the-art infrastructure, developers will have direct access to the experienced team for assistance with process optimisation, scale-up, validation, and qualification capabilities.
This expansion is aimed at supporting late-phase drug developers as the field of mRNA-based therapeutics and vaccines advances and enters later-stage clinical trials.
The construction of these new manufacturing capabilities signifies in advancing the field and supports the development of innovative treatments.
The new facility is expected to be completed in early 2024